Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00225524

Enrollment

150

Registered

2005-09-23

Start date

2004-09-30

Completion date

Unknown

Last updated

2007-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression

Brief summary

Phase III long-term safety study of Effexor XR in patients with major depression.

Interventions

DRUGEffexor XR

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)

Exclusion criteria

* Patients with schizophrenia or any other psychotic disorder * Patients with history or presence of bipolar disorder

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events	—

Secondary

Measure	Time frame
Quantitative data for laboratory data	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026